Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

Show full item record




Malani , D , Murumagi , A , Yadav , B , Kontro , M , Eldfors , S , Kumar , A , Karjalainen , R , Majumder , M M , Ojamies , P , Pemovska , T , Wennerberg , K , Heckman , C , Porkka , K , Wolf , M , Aittokallio , T & Kallioniemi , O 2017 , ' Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML ' , Leukemia , vol. 31 , no. 5 , pp. 1187-1195 . https://doi.org/10.1038/leu.2016.314

Title: Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
Author: Malani, D.; Murumagi, A.; Yadav, B.; Kontro, M.; Eldfors, S.; Kumar, A.; Karjalainen, R.; Majumder, M. M.; Ojamies, P.; Pemovska, T.; Wennerberg, K.; Heckman, C.; Porkka, K.; Wolf, M.; Aittokallio, T.; Kallioniemi, O.
Contributor organization: Institute for Molecular Medicine Finland
Olli-Pekka Kallioniemi / Principal Investigator
University of Helsinki
Department of Oncology
Hematologian yksikkö
Department of Clinical Chemistry and Hematology
Krister Wennerberg / Principal Investigator
Tero Aittokallio / Principal Investigator
HUS Comprehensive Cancer Center
Precision Systems Medicine
Date: 2017-05
Language: eng
Number of pages: 9
Belongs to series: Leukemia
ISSN: 0887-6924
DOI: https://doi.org/10.1038/leu.2016.314
URI: http://hdl.handle.net/10138/195929
Abstract: We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated AML patients. The models and patient cells were subjected to genomic and transcriptomic profiling and high-throughput testing with 250 emerging and clinical oncology compounds. Genomic profiling uncovered deletion of the deoxycytidine kinase (DCK) gene in both MOLM-13- and SHI-1-derived cytarabine-resistant variants and in an AML patient sample. Cytarabine-resistant SHI-1 variants and a subset of chemorefractory AML patient samples showed increased sensitivity to glucocorticoids that are often used in treatment of lymphoid leukemia but not AML. Paired samples taken from AML patients before treatment and at relapse also showed acquisition of glucocorticoid sensitivity. Enhanced glucocorticoid sensitivity was only seen in AML patient samples that were negative for the FLT3 mutation (P = 0.0006). Our study shows that development of cytarabine resistance is associated with increased sensitivity to glucocorticoids in a subset of AML, suggesting a new therapeutic strategy that should be explored in a clinical trial of chemorefractory AML patients carrying wild-type FLT3.
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc_sa
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
leu2016314a.pdf 1.043Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record